Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Have Been Previously Treated With Imatinib and Have Not Achieved Deep Molecular Response.
Novartis
Novartis
Medical College of Wisconsin
Celgene
Takeda
Medical College of Wisconsin
H. Lee Moffitt Cancer Center and Research Institute
Medical College of Wisconsin
Pfizer
Seagen Inc.
National Heart, Lung, and Blood Institute (NHLBI)
Sierra Oncology LLC - a GSK company
National Heart, Lung, and Blood Institute (NHLBI)
Hoffmann-La Roche
Novartis
M.D. Anderson Cancer Center
Gilead Sciences
M.D. Anderson Cancer Center
Fred Hutchinson Cancer Center
Seagen Inc.
Seagen Inc.
M.D. Anderson Cancer Center
Seagen Inc.
National Institutes of Health Clinical Center (CC)
Sunesis Pharmaceuticals
Stanford University
M.D. Anderson Cancer Center
Seagen Inc.
Seagen Inc.
Seagen Inc.
Seagen Inc.
M.D. Anderson Cancer Center
Seagen Inc.
M.D. Anderson Cancer Center
University of Chicago
H. Lee Moffitt Cancer Center and Research Institute
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center